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Tuberous sclerosis complex (TSC) is characterized as a rare hereditary disorder impacting an 
estimated 25,000-40,000 persons in the United States and 1-2 million persons worldwide (Song 
et al., 2017). Individuals with TSC have extensive comorbidities that affect their health-related 
quality of life, healthcare utilization, and expenditure. The current literature lacks documentation 
on the impact of the various comorbidities and their association with healthcare utilization and 
expenditures among individuals with TSC.  The purpose of this dissertation study was to 
examine the trends in healthcare utilization (emergency department and inpatient admission) and 
expenditures that can be identified among individuals diagnosed with TSC, with and without 
epilepsy.  Multivariate analysis was conducted to compare the proportions of TSC patients with 
epilepsy to the proportions of TSC patients without epilepsy, with regards to the use of inpatient 
hospital (IP) care, emergency room (ER) use, and total expenditures.  Among the 3,572 patients 
analyzed, 65.5% of the study population were TSC patients with epilepsy, compared with 34.5% 
of patients without epilepsy.  Approximately 81% of the patients had between one to ten 
comorbidities and the expected primary payer for most patients (67%), was public health 
insurance (26% Medicare, and 40.7% Medicaid).  The odds of hospital admission were nearly 
two-fold higher among those with epilepsy (OR and CI). This finding indicated that increased 
ED use among TSC patients with epilepsy may also lead to increased hospitalization. The overall 
mean annual expenditure for ED visits by TSC patients without epilepsy was slightly lower than 
that for patients with epilepsy. However, for an inpatient stay, TSC patients without epilepsy had 
higher total expenditures ($63,520) compared with TSC patients with epilepsy ($40,248).  
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TUBEROUS SCLEROSIS COMPLEX, EPILEPSY 
1 
 
Chapter 1: Introduction 
Introduction to the Chapter 
Tuberous sclerosis complex (TSC) is characterized as a rare hereditary disorder 
impacting an estimated 25,000-40,000 persons in the United States and 1-2 million persons 
worldwide (Song et al., 2017). TSC affects multiple organ systems, including the brain, kidneys, 
lungs, heart, and skin.  However, the manifestation of the disease is highly diverse and varies 
significantly among individuals impacted (Northrup & Krueger, 2013).  This rare genetic 
disorder mutates in the TSC1 on chromosome 9q34 and the TSC2 on chromosome 16p13 (Toldo 
et al., 2019; Curatolo, Bombardieri, & Cerminara, 2006), causing benign tumors in the brain, 
kidneys, heart, lungs, liver, eyes, and skin (Sun et al., 2015).  People with TSC have an increased 
risk of developing epilepsy due to the disruption of a TSC gene expression in the brain, leading 
to cerebellar atrophy, abnormal cellular growth, migration, and proliferation (Curatolo, 2015; 
Moavero, Cerminara & Curatolo, 2010).  There is significant variability in the clinical 
presentation of TSC based on the characteristics associated with the onset of lesions coupled 
with neurological manifestations, such as epilepsy and neurodevelopmental disorders 
(Almobarak et al., 2018; Hallett et al., 2011). 
Although various types of comorbidities (benign neoplasm of the kidney, malignant 
neoplasm of the brain, epilepsy, autism, ulcerative colitis, and mood disorders) occur in 
individuals with TSC, neurological disease (disorders of the nervous system) is arguably the 
most important clinical issue.   Epilepsy is one of the most common comorbid conditions among 
individuals with TSC, with an onset of seizures occurring during the first year of life (Nabbout et 
al., 2019).  Current estimates suggest 80-85% of all TSC patients develop epileptic seizures, with 
two-thirds who are not responsive to antiepileptic treatment (Curatolo et al., 2018; Overwater et 




al., 2015; Moavero, Cerminara, & Curatolo, 2010).  The multiple comorbidities associated with 
TSC and its effects on various organ systems indicate a significant health care and disease 
burden, as well as a substantial economic burden on individuals, their families, and society. 
Statement of the Problem 
TSC inflicts a burden on society by imposing a significant toll on both the individuals 
who have the condition and their families and caregivers.  Individuals with TSC are at risk of 
poor health outcomes; however, those associated with epileptic seizures are at an even greater 
risk of poor health outcomes, along with constant use of health care and higher health-care costs.  
The burden of disease management for TSC is well established in the literature; however, 
there is limited available evidence of healthcare utilization and expenditure.  In a systematic 
review of the TSC literature, Hallett et al. (2011) concluded there is limited economic and 
humanistic outcome research in this population, representing an important knowledge gap in the 
cost of illness and treatment.  
The goal of this dissertation study is to quantify and compare healthcare utilization and 
expenditure among individuals diagnosed with TSC with and without epilepsy.  Factors 
including socio-economic status, clinical impact, and cost-effectiveness of treatment will be 
explored.   More importantly, understanding the profile and cost of healthcare utilization of these 
individuals using real-world data is critical for (a) quantifying the existing burden on the 
healthcare system, (b) identifying areas of sub-standard care for various comorbidities associated 
with this disorder, (c) estimating future healthcare utilization and expenditures, and (d) bridging 
the gap in currently published literature. 




Research Question  
This dissertation study examined and compared healthcare utilization and expenditures 
among individuals diagnosed with TSC, with and without epilepsy. The central guiding 
questions to be examined in this study are as follows: 
Question:  What trends associated with healthcare utilization (emergency department use 
and inpatient admissions) and expenditures can be identified among individuals 
diagnosed with TSC with and without epilepsy?  
Aim 1: To determine the healthcare utilization (inpatient and emergency 
department) among individuals diagnosed with TSC with and without epilepsy. 
Aim 2: To determine the specific costs associated with the care of these 
individuals. 
Aim 3: To determine the prevalence and impacts of predisposing comorbidities on 
hospital admissions and expenditures among individuals with TSC who are 
diagnosed with epilepsy.  
Aim 4: To determine the socio-demographic and patient dispositions among 
individuals with TSC that are associated with epilepsy. 
Relevance and Significance 
TSC is characterized as a rare hereditary disorder impacting an estimated 25,000–40,000 
persons in the United States and 1–2 million persons worldwide (Song et al., 2017).  Individuals 
with TSC have an increased risk of developing epilepsy, which is considered as one of the most 
common comorbid conditions.  Although seizures are a hallmark manifestation of TSC, there is a 
paucity of data in the public domain characterizing healthcare resource utilization and 
expenditure in the TSC population. 




Little has been published in the last 10 years describing healthcare utilization and 
expenditure burden of TSC and even less for individuals with comorbid epileptic seizures. A 
search of the literature on healthcare utilization and expenditures of individuals with TSC 
associated with epilepsy resulted in locating few publications: two studies conducted in the 
United States, one in the United Kingdom, and one in Sweden.  The absence of robust literature 
of direct and indirect costs associated with TSC, and specifically in conjunction with epilepsy, 
prevents an accurate assessment of the economic burden (Hallett et al., 2011) 
  Lennert et al. (2013) characterized resource utilization in a small cohort over 5 years in 
patients with TSC and associated seizures in the US.  This study revealed that hospitalization 
was common in 83.2% of TSC patients, with a mean of 0.50 per year/patient and an average 
length of stay of 6.22 days. Furthermore, neurologic-related hospitalizations accounted for a 
mean number of 0.28 per year/patient and an average stay of 6.03 days (Lennert et al., 2013).  A 
similar study conducted recently in the US to examine TSC health care utilization based on the 
National Inpatient Sample Database (NIS) using a dataset from the years 2000-2010 revealed 
that of the 5,655 patients studied, 41.2% had epilepsy and an overall median total hospitalization 
charge of $14,807 across all years (Wilson et al., 2016).  A study conducted in the United 
Kingdom examining the economic burden of TSC associated with epilepsy over a 3-year period 
found patients incurred costs of £14,335 (U.S. equivalent of $18,449) on average, with a 
significant proportion of costs attributed to inpatient admissions (Shepherd et al., 2017).  Lastly, 
a study conducted in Sweden to estimate the prevalence, manifestations, treatments, healthcare 
utilization, and mortality of TSC patients with epilepsy found that patients with refractory 
epilepsy (specifically those with infantile spasm) had the highest mean healthcare utilization 
(Welin et al., 2017).   Other relevant TSC studies examining healthcare utilization and 




expenditure include (a) a study in France by Chevreul et al. (2015) that estimated an average 
annual cost of  EUR 22,459 ( U.S. equivalent of $24,953)  per patient for Systemic Sclerosis 
(SSc), (b) Vekeman et al.’s (2015) study in the Netherlands examining individuals with TSC 
associated with cyclin-dependent kinase (CKD) revealed an average expenditure of EUR 1,275- 
31,916 ( U.S. equivalent of $ 1,566 – 39,215) annually in 2012, (c) a study in the United 
Kingdom by Kingswood et al. (2016) that estimated the average expenditure of  £12,681(U.S. 
equivalent of $16,336) per person over the 3 years among individuals with TSC, and (d) a study 
in the United States that estimated TSC patients with subependymal giant cell astrocytoma 
(SEGA) had a mean expenditure of  $85,397 (Sun et al., 2015), and TSC renal angiomyolipoma 
(AML) patients with mean total healthcare costs ranging from $29,240-$48,499 (Song et al., 
2017).   
The economic burden among individuals with TSC associated with epilepsy remains 
poorly understood, with little evidence describing how the disease-associated costs impact 
patients, caregivers, and society.  The need for improvement in healthcare utilization and 
expenditure related to the management and care for these individuals is essential to promote 
adequate disease control and improve health and social outcomes. The findings from this 
dissertation study will provide public health practitioners, health care providers, policymakers, 
and other TSC stakeholders with healthcare utilization and expenditure data for this population.  
The availability of such data ensures that evidence-based programs, supportive services, and 
disease management meet the complex needs of individuals with TSC associated with epileptic 
seizures. 
Definition of Terms 
The following definitions of terms are important in the understanding of this dissertation study:  




 Epilepsy.  Epilepsy is a chronic disease characterized by sudden recurrent and 
unprovoked episodes of neurological disturbance, loss of consciousness, and convulsions 
triggered by abnormal brain activity (Epilepsy Society, n.d.). 
Seizure.  A seizure is a sudden surge of electrical activity in the brain that usually affects 
how an individual appears or acts for a brief period (Epilepsy Foundation, n.d.).  According to 
the epilepsy foundation, there are variations with the nature of seizures.  These variations are due 
to the particular lobe of the brain which controls different behaviors, movements, and 
experiences (Epilepsy Foundation, n.d.). 
Health Disparity.  Health disparity is defined by the Centers for Disease Control and 
Prevention as preventable differences caused by the burden of disease, poverty, environmental 
threats, inadequate access to health care, and lack of opportunities to achieve optimal health 
(CDC.gov, n.d.). 
 Healthcare Utilization.  Healthcare utilization is the measure of a population’s use of 
healthcare services such as utilization of hospital resources, personal home care resources, and 
physician resources available to them (Manitoba Center for Health Policy, n.d.). 
 Socio-Economic Status (SES).   SES is considered as the social standing or class 
(educational level, income, and occupation) of an individual or group (American Psychological 
Association, n.d.).  
International Classification of Diseases, Ninth Revision (ICD-9).  ICD9 is the official 
system of assigning codes to diagnoses and procedures associated with hospital utilization in the 
United States. 




Summary of the Chapter 
This chapter introduced the research problem and gaps in the literature regarding 
healthcare utilization and expenditure in TSC patients with epilepsy. It also presented the 
research questions to be explored, highlighted the study’s implications for healthcare providers 
and public policy, and described the importance of access to evidence-based data to aid 
supportive services and disease management to meet the needs of the individuals impacted by 
TSC. 




Chapter 2: Review of the Literature 
Introduction to the Chapter 
This literature review chapter presents an introduction to tuberous sclerosis complex and 
epilepsy, a theoretical framework, and existing research that underpins the basis for this 
dissertation study. 
Tuberous Sclerosis Complex (TSC) 
TSC was first described by von Recklinghausen when he presented a full-term stillborn 
infant whose brain contained several sclerotic areas post-partum in 1862 (Roach, 2016).  
Eighteen years later, a researcher named Bourneville characterized a baby’s brain pathology as 
“sclérose tubéreuse des circonvolution cérébrales,” the name used to describe the disorder 
(Roach, 2016).  Bourneville in 1980 used the term “tuberous sclerosis of the cerebral 
convolutions” when describing the potato-like appearance of the cerebral lesion observed 
(Curatolo, Moavero, & de Vries, 2015). 
TSC is considered one of the most common neurocutaneous disorders involving multiple 
organ systems (DiMario, Sahin, & Ebrahimi-Fakhari, 2015). It presents variably during infancy, 
childhood, and early adulthood in all ethnic groups and both sexes (DiMario, Sahin, & Ebrahimi-
Fakhari, 2015).  This rare genetic disorder results in the mutation of the TSC1(encoding 
hamartin) gene on chromosome 9q34, and TSC2 (encoding tuberin) gene on chromosome 16p13 
(Toldo et al., 2019), causing benign tumors in the brain, kidneys, heart, lungs, liver, eyes, and 
skin (Sun et al., 2015).  Mutations in the TSC1 or TSC2 gene lead to disruption of the TSC1-
TSC2 intracellular protein complex (Curatolo et al., 2015), causing overactivation of the 
mammalian target of rapamycin (mTOR) protein (responsible for the coordination of several 
facets of cell functioning, including cell growth, metabolism, and proliferation; Slowinska et al., 




2018).     mTOR, is a serine/threonine kinase found in two distinct complexes, mTOR complex 
1(mTORC1) and mTOR complex 2 (mTORC2; Curatolo at al, 2015).  mTORC1 regulates 
protein synthesis, gene transcription, and cell cycle progression and survival, while mTORC2 
has a role in mediating cytoskeletal dynamics (Franz & Capal, 2017).  Abnormalities associated 
with the mTOR pathway are believed to contribute to the development of many cancers, TSC, 
and other neurologic disorders (Franz & Capal, 2017).  Mutations in the TSC1 gene account for 
10% of TSC cases, while the TSC2 gene is associated with an estimated 90% of the clinical 
cases (Crino et al., 2006).    
Prevalence, Clinical Characteristics, and Diagnosis of TSC 
The occurrence of tuberous sclerosis complex is estimated to be as high as 1:5,800 live 
births with a high mutation rate of 1:250,000 per gene, per generation (Northrup et al., 1999 
[Updated 2018]).  The population prevalence of TSC is estimated to be about 25,000-40,000 
persons in the United States and 1-2 million persons worldwide (Song et al., 2017).   
The clinical features of TSC manifest differently from person to person and are highly 
variable and age-dependent (Roach, 2016).  Although neurological and neuropsychiatric 
manifestations (manifestations in the brain, seizures, intellectual disability, developmental delay, 
and psychiatric illness) are the major sources of morbidity and mortality, most patients present 
clinical findings of various comorbid manifestations (Curatolo et al., 2015).  Tumors occurring in 
the central nervous system (CNS) are among the leading causes of mortality and morbidity in 
TSC patients (Northrup et al., 1999/2020).   These brain tumors, found in TSC patients include 
subependymal nodules (SENs), which occur in 80% of individuals, cortical dysplasia, occurring 
in 90% of individuals, and subependymal giant cell astrocytomas (SEGAs), occurring in 5-15% 
of all individuals (Northrup et al., 1999/2020]).   Seizures affect more than 75% of TSC patients, 




and about 50% have a developmental delay or intellectual disability (Curatolo et al., 2018; 
Kingswood et al., 2017).  Neuropsychiatric manifestations present in most individuals with TSC 
are characterized as tuberous-sclerosis-associated neuropsychiatric disorders (TAND; Curatolo et 
al., 2015).  TAND includes manifestations that are behavioral, intellectual, and psychosocial.   
Individuals with TSC are also at high risk for autism spectrum disorder (ASD), with recent 
estimates of 16 - 61% (Kingswood et al., 2017) 
Non-neurological manifestations, including dermatological manifestations (the 
appearance of hypomelanotic macules (90%), angiofibromas (75%), fibrouscephalic plaques 
(25%), ungual fibromas (20%), shagreen patches, and confetti skin lesions) are often the first 
sign of TSC (Curatolo et al.,) with the skin affected in all TSC patients (Northrup et al, 1999 
[Updated 2020]).  In addition, cardiac rhabdomyomas, which occur in 60% of individuals with 
TSC are considered to be part of the initial identifiable manifestations of the disorder and can 
play a major role in the diagnosis of TSC (Curatolo et al., 2015).  Manifestations in the kidney 
(angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs 
(lymphangioleiomyomatosis, multifocal micronodular pneumonocyte hyperplasia) are other non-
neurological manifestations present in individuals with TSC (Northrup et al, 1999/2018).  Table 















Table 1  





























Ungual fibromas  
Characterized as ("ash leaf 
spots") patches of skin that 
may appear anywhere on the 
body and are caused by a 
lack of melanin. 
 
Stippled hypopigmentation, 
typically on the extremities. 
Characterized by red papules 
on the malar region. 
 
An irregularly shaped, 
slightly elevated soft skin-
colored patch, usually on the 
lower back, made up of 
excess fibrous tissue.  
 
Nodular or fleshy lesions that 
arise adjacent to or from 
underneath the nails. 
 
 
Fibrous growths that are 
located around the 
fingernails or toenails 
Hypomelanotic macules are 
estimated to occur in 
approximately 90% of 
individuals with TSC 
(Northrup et al, 1999/2018). 
 
Confetti skin lesions occurs in 




Facial angiofibromas occur in 
approximately 75% of 
individuals with TSC 
(Northrup et al, 1999/2018). 
 
 
Shagreen patches occur in 
approximately 50% of 
individuals with TSC 
(Northrup et al, 1999/2018). 
 
Ungual fibromas occur in 
20% overall but ≤80% in 
older affected adults 




















Small nodular masses which 
originate in the 
subependymal region of the 
lateral ventricles and 
protrude into the ventricular 
cavity. 
 
Malformation of the cerebral 
cortex due to improper 




Northrup & Krueger (2013), 
estimate the prevalence of 
SENs to occur in 80% of 




Cortical dysplasias affect 
approximately 90% of 
individuals with TSC 
(Northrup & Krueger, 2013). 
 
 
























Tumors commonly located 




A sudden, uncontrolled 




Characterized by the 
manifestation of brain 






A developmental disorder 
that affects communication 
and behavior. 
SEGAs are estimated to occur 
in 5%-20% of all individuals 
with TSC (Kothare et al. 
2014).   
 
An estimate of >80% of 
individuals with TSC has 
been reported to have seizures 
(Northrup et al, 1999/2018).   
 
An estimated 90% of 
individuals with TSC exhibit 






Approximately 16% to 61% 
of individuals with TSC 
develop characteristics of 
ASD with disease 
manifestation occurring as 
early as the age of nine 












Renal Cystic disease  
 
Characterized as a benign 
tumor of the kidney, can 
grow such that kidney 




Characterized by the 
development of numerous 
fluid-filled cysts in the 
kidneys. 
 
Renal disease occurs in an 
estimated 80% of individuals 
with TSC.  Angiomyolipomas 
and cysts are the most 
common pathology observed 
(Rakowski et al. 2006).  
 
 Clinically detectable renal 
cystic disease occurs in 
approximately 50% of 
patients with TSC (Dixon, 







A common primary tumor of 
the heart in infants and 
children that degenerates 
over time and eventually 
disappear. 
 
Approximately 47%-67% of 
individuals with TSC presents 
Cardiac rhabdomyomas 
(Northrup et al, 1999/2018). 
    





matosis (LAM)  
Pulmonary disorder that 
typically presents in early 
adulthood 
LAM is estimated to occur in 
approximately 34% of 





Retinal hematomas  
 
Typically, asymptomatic and 
are not progressive, but they 
may obstruct vision in some 
patients 
 
Retinal hematomas are 
estimated in approximately 
50% of individuals with TSC 
(Rosser, Panigrahy & 
McClintock, 2006).   
 
A diagnosis of TSC can be made after careful clinical examination coupled with selected 
organ imaging, laboratory testing, and genetic evaluation (DiMario, Sahin, & Ebrahimi-Fakhari, 
2015).  The criteria for TSC diagnosis were revised at the International TSC Consensus 
Conference in 2012.  The primary mode of diagnosis includes a genetic criterion as well as 
clinical features.   According to the revised diagnosis criteria (Table 3), a definitive diagnosis of 
TSC can be made in the presence of a pathogenic TSC1 or TSC2 mutation, and a possible 
diagnosis is made when either 1 major feature or greater than 2 minor features are present 
(Curatolo et al., 2015).  The presence of specific disease symptoms is rare; however, individuals 
with TSC present several common characteristics that require further investigation, such as 
(a)identification of family member with TSC, (b) identification of cardiac rhabdomyomas, (c) 
postnatal identification of hypopigmented macules on the skin, and (d) the development of 
seizure (DiMario et al., 2015). 
Table 2 
Diagnostic criteria according to the International Tuberous Sclerosis Complex Consensus 
Conference 
 
Diagnostic criteria for TSC 
Definite diagnosis: presence of a pathogenic TSC1 or TSC2 or two major clinical features 
Possible diagnosis: presence of either 1 major feature or greater than 2 minor features  




Major Criteria / Features 
Skin/oral cavity Hypomelanotic macules (n>3, at least 5 mm diameter) 
Angiofibromas (n>3) or fibrous cephalic plaque 





Cortical dysplasias (includes tubers and cerebral white matter radial 
migration lines) 
Subependymal nodules 
Subependymal giant cell astrocytoma 
Heart Cardiac rhabdomyoma 
Lungs Lymphangioleiomyomatosis 
Kidney Angiomyolipomas (n>2) 
Eyes Angiomyolipomas (n>2) 
Minor Criteria / Features 
Skin/oral cavity “Confetti” skin lesions 
Dental enamel pits (n>3) 
Intraoral fibromas (n>2) 
Kidney Multiple renal cysts 
Eyes Retinal achromic patch 
Other organs Nonrenal hamartomas 
Tuberous Sclerosis Complex and Epilepsy 
Epileptogenesis is a chronic process by which a normal brain, often triggered by genetics 
or acquired factors, develops epilepsy (Curatolo et al., 2018).  The presence of cortical tubers 




(dysplastic neurons, giant balloon cells, and glial components) are attributed to the development 
of epilepsy in individuals with TSC (Jeong & Wong, 2016).   Experimental studies suggest a 
mutation of the TSC gene along with mTOR overactivation (Fig 1), resulting in the early 









Adapted from, Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., ……. Jóźwiak, S. (2018). 
"Management of epilepsy associated with tuberous sclerosis complex: Updated clinical 
recommendations." European Journal of Paediatric Neurology. 
 
Epileptic seizures affect 80-85% of individuals with TSC and are the most common 
neurological comorbidity, with a significant incidence of morbidity and mortality (Almobarak et 




al., 2018; Nabbout et al., 2019).  These seizures are not sudden occurrences, but rather a 
progressive change that can be detected early in life through EEG synchronization and 
appearance of focal or multifocal epileptiform activity (Cusmai et al., 2011).  Clinical 
investigations by researchers have indicated a high incidence of abnormalities in EEG patterns 
and epileptiform features (Thiele, 2014).  Experimental studies have suggested that the early 
onset of epileptic seizures and the severity of the seizures may be attributed to a deficiency of 
GABAergic interneurons, delayed GABA excitation, disruption of GABAergic interneuron 
migration, and/or alterations in GABA-A receptors (Cusmai et al., 2011).  While many types of 
seizures are seen in individuals with TSC, infantile spasms are the most common and often 
manifest during the first year of life (Curatolo et al., 2018). Other manifestations of epilepsy in 
TSC patients include focal to bilateral tonic-clonic, atypical absence, myoclonic, and generalized 
tonic-clonic seizures (Almobarak et al., 2018). 
Diagnosis of Tuberous Sclerosis Complex Associated with Epilepsy 
The diagnosis of TSC as accepted and recommended by the Tuberous Sclerosis 
Consensus Conference in 2012 is based on the emergence of a pathogenic mutation (present in 
75-90% cases) in either TSC1 or TSC2 gene (Slowinska et al., 2018).  Other diagnostic criteria 
for TSC include the presence of cardiac rhabdomyomas, dermatological findings with 
hypomelanotic macules, ophthalmological changes, and renal manifestations (Slowinska et al., 
2018).  In a large TSC registry study conducted by Ebrahimi-Fakhari et al. (2018), the median 
age of diagnosis was one year.  In most individuals, the diagnosis of TSC is made after the onset 
of seizures (Slowinska et al., 2018).  A study conducted by Jeong and Wong (2016) 
demonstrated that brain activity characterized by cortical tuber hamartomas was linked to an 
increased risk of epilepsy in individuals with TSC.  Ebrahimi-Fakhari et al. (2018) found that 




CNS involvement with seizure disorders was the most common clinical symptom at diagnosis of 
TSC and had a prevalence rate of 69.8%.  Lastly, Chung et al. (2017) explained that the presence 
of interictal epileptiform discharges (patterns of activity between seizures) and electrographic 
seizure activity on EEG are precursors to the onset of seizures in individuals with TSC.  
Treatment of Epilepsy Associated with Tuberous Sclerosis Complex 
Individuals with TSC are at risk of poor health outcomes; those with epileptic seizures 
have an even higher risk. The goal of epilepsy treatment in individuals with TSC is to prevent the 
occurrence of seizures, thus maximizing the opportunity to improve cognitive development and 
overall quality of life (Curatolo et al., 2018; Curatolo, Jozwiak, & Nabbout, 2012). Treatment of 
epilepsy in individuals with TSC is considered difficult despite the availability of several options 
in the management of the disease.  A study conducted by Song et al. (2019) reported that nearly 
all (92.3%) of the patients in the study received non-surgical and/or surgical treatment for the 
management of epileptic seizures, with 99.5% receiving antiepileptic drugs (AEDs).  This study 
also reported a large proportion of patients who initiated multiple AEDs, corroborating an earlier 
study by Overwater et al. (2015) that reported more than half of all patients studied had 
refractory (uncontrolled or drug-resistant) epilepsy.   
Although epilepsy treatment in individuals with TSC is refractory for most, treatment 
options tend to be similar to those for non-TSC-associated diagnoses, including the use of AEDs 
as well as nonpharmacologic approaches.  AEDs such as topiramate, lamotrigine, 
carbamazepine, valproic acid, and levetiracetam have all been found to be effective and well-
tolerated in this population (Canevini et al., 2018). Nonpharmacologic options include surgery, 
ketogenic diet, and vagus nerve stimulation (Song et al., 2018; Curatolo, Jozwiak, & Nabbout. 
2012). 




Pharmacologic Treatment Options 
Antiepileptic drugs are commonly used in the management of epilepsy in TSC and are 
considered to be first-line therapy (Song et al., 2018).  Current literature indicates that one-third 
of the children with TSC develop infantile spasms (Canevini et al., 2018), a rare epileptic 
disorder that occurs in young children.  The International TSC Consensus Conference, a panel of 
TSC experts, recommended vigabatrin (VGB) as the first-line therapy for infants and AEDs with 
c-aminobutyric acid (GABA)ergic mechanisms for older children (Overwater et al., 2015).  In a 
study conducted by Marques et al. (2019), the most common treatment for TSC patients with 
epilepsy was GABAergic agents (e.g., vigabatrin), both in mono and combination therapy.  
Vigabatrin, an inhibitor of GABA transaminase, is considered to be the most effective AED in 
infants with spasm and other seizures (Canevini et al., 2018; Jozwiak et al., 2011).  Other AEDs 
such as valproic acid, levetiracetam, clobazam, lamotrigine, topiramate, oxcarbazepine, 
carbamazepine, and adrenocorticotropic hormone have all been found to be effective in treating 
epileptic seizures in individuals with TSC (Marques et al., 2019; Overwater et al., 2015).  In an 
open-label prospective patient chart review conducted by Overwater et al. (2015), the most 
commonly used AEDs in TSC were valproic acid (85%), vigabatrin (61%), levetiracetam (46%), 
carbamazepine (41%), and clobazam (41%).  Literature from emerging studies also suggests that 
the mechanistic target of rapamycin (mTOR) inhibitors may improve seizure and developmental 
outcomes in TSC patients (Marques et al., 2019; Chung et al., 2017).  mTOR activation can 
result in increased neuroexcitability and seizures, thus mTOR inhibitors such as sirolimus 
(rapamycin) and everolimus work by inhibiting mTOR signaling events (Curatolo et al., 2018).  
Results from a randomized control trial conducted by French et al. (2016) to investigate 
everolimus therapy for treatment-resistant seizures associated with TSC showed a significant 




reduction in seizure frequency and improvement in seizure control.  Although there are various 
AEDs available for the treatment of epilepsy in individuals with TSC, many of these individuals 
develop seizure disorders that are pharmacoresistant.  Table 3 illustrates the various 
pharmacologic treatment options for individuals with TSC associated with epilepsy. 
Table 3 
Pharmacologic options for treatment of epilepsy associated with Tuberous Sclerosis Complex 
 
Drug Drug Class Indication Treatment 
Recommendation 
Vigabatrin Anti-epileptic, Gamma 
amino acids and 
derivatives 
For use in treatment 
resistant epilepsy, 
refractory complex 
partial seizures, and 
secondary generalized 
seizures. 
Monotherapy in TSC 





Carboxylic acids and 
derivatives 
For treatment and 
management of seizure 
disorders such as 
infantile spasm 
Monotherapy for TSC- 
related infantile spasm.   
Everolimus Protein Kinase inhibitor, 
Antineoplastic Agent 
For the treatment of TSC 
associated with seizures 
Adjunctive treatment of 
adult and pediatric 
patients aged 2 years and 




Valproic acid   Anticonvulsants For treatment and 
management of seizure 
disorders such as 
absence seizures, tonic-
clonic, and complex 
seizures. 
Monotherapy and 
adjunctive therapy for 
complex partial seizures 
that occur either in 
isolation or in association 
with other types of 
seizures 
Levetiracetam Anticonvulsants, 
Carboxylic acids, and 
derivatives 
Used to treat partial-
onset seizures in adults 
and children who are at 
least 1 month old 
Adjunctive therapy in the 
treatment of partial-onset 
seizures in adults and 
children 4 years of age 
and older with epilepsy.  






Used for the treatment of 
partial or complex partial 
seizures 
Adjunctive therapy in 
both children and adults. 
Clobazam Benzodiazepines, 
Anticonvulsant. 
For treatment and 
management of epilepsy 
and seizures associated 
with Lennox-Gastaut 
syndrome, a difficult-to-
treat form of childhood 
epilepsy. 
Adjunctive therapy in 
patients 2 years and older. 
Lamotrigine Anticonvulsants, 
Benzene, and substituted 
derivatives 
Used either alone or in 
combination with other 
medications to treat 
epileptic seizures in 
adults and children. 
Adjunctive therapy for 
seizures in patients ≥2 
years of age and 
monotherapy in adults 




used primarily for the 
treatment of epilepsy. 
Monotherapy or 
adjunctive therapy in the 
treatment of partial 
seizures in adults with 
epilepsy and as adjunctive 
therapy in the treatment of 
partial seizures in children 




Used for the treatment of 
epilepsy in children and 
adults. 
Monotherapy for partial-
onset or primary 
generalized in patients 
over 2 years of age. 
Adjunctive therapy for 
partial-onset seizures 
adults.  
Non-Pharmacologic Treatment Options 
The evaluation of nonpharmacologic options early during treatment is important due to 
the refractory nature of AEDs among patients with epilepsy.  Nonpharmacologic epilepsy 
treatments shown to be effective in patients with TSC are the ketogenic or low glycemic index 
diet, epilepsy surgery (Overwater et al., 2015), and vagus nerve stimulation (Connolly, Hendson, 
& Steinbok, 2006).  




Epilepsy Surgery. Surgical treatment of epilepsy in children and adults with TSC has 
gained significant interest in recent years, although surgical management proves to be complex 
and challenging.  The complexities are due to challenges associated with epileptogenic tuber 
complexes merging subtly with each other, and involvement of more than one region of the brain 
(Gupta, 2017).   The effectiveness of epilepsy surgery has been shown in patients with refractory 
epilepsies, with seizure freedom achieved in 50-60% of patients (Fohlen et al., 2018).    This is 
consistent with a systematic review of literature by Jansen et al. (2007) that showed the 
successful outcome of epilepsy surgery in patients with drug-resistant epilepsy and tuberous 
sclerosis.  Among these patients, the authors concluded that seizure freedom was achieved in 
57% of the patients, and seizure frequency improved by >90% in 18% of patients (Jansen et al., 
2007).  A long-term study conducted by Liang et al. (2017) also reported satisfactory seizure 
freedom in 74.5% of the patients with TSC one year after surgery, 58.8% at five years after 
surgery, and 47.8% ten years after surgery.  To ensure better outcomes and seizure improvement 
in TSC patients, candidates for epilepsy surgery should be carefully selected based upon a 
comprehensive imaging and electrophysiological data, as well as invasive EEG recordings to 
ensure the accurate identification of epileptogenic zones (Fohlen et al., 2018). 
 Ketogenic Diet. The ketogenic diet as a treatment for epilepsy and seizure control has 
been documented in the medical literature for over 80 years.    New variations of the ketogenic 
diet have emerged in the last decade, including the modified Atkins diet and the low-glycemic-
index diet.  The ketogenic diet can be an effective option in the management of epilepsy in 
patients with TSC, particularly younger patients for whom surgery is not appropriate (Kossoff et 
al., 2018; Martin‐McGill et al., 2018; Curatolo et al., 2012).  The ketogenic diet has been shown 
to have the ability to reduce mTOR activation in animal models, thus providing a scientific basis 




for its mechanism of action in TSC-associated seizures (Curatolo, 2018).  Liu et al. (2018) 
reported evidence of significant positive outcomes with the ketogenic diet for the treatment of 
refractory epilepsy.  In this study, analysis of patients with drug-resistant epilepsy showed that 
the ketogenic diet was effective with 13% of the patients achieving seizure freedom and over 
50% of the patients achieving seizure reduction by more than 50%.  Similarly, a randomized 
controlled trial conducted by Ijff et al. (2016) showed a positive cognitive and behavioral effect 
of the ketogenic diet in children and adolescents with refractory epilepsy.  For clinical 
management of seizures, the ketogenic diet has been highly recommended for individuals and 
specifically children who have failed more than two antiseizure medications (Kossof et al., 
2018). 
Vagus Nerve Stimulation (VNS).  VNS is a common neuromodulation based 
intervention in patients with inadequately controlled seizures (Gonzalex, Yengo-Kahm, & 
Englot, 2019). It is approved as an adjunctive therapy by the U.S. Food and Drug Administration 
(FDA) for use in individuals 4 years and older with intractable partial-onset seizures.  There is 
limited literature regarding the use of vagus nerve stimulation in individuals with tuberous 
sclerosis and refractory seizures. However, VNS has been proven to be an effective and safe 
treatment for intractable epilepsy (Zamponi et al., 2010).  In a small cohort study of individuals 
with TSC, Parain et al. (2001) demonstrated the efficacy of using VNS as a mechanism for 
seizure control. A similar study conducted by Elliott et al. (2009) in a small cohort of 19 patients 
with refractory epilepsy and TSC further supports the use of VNS as a safe and effective 
treatment option.  In this study, 82% of the patients experienced a 67% reduction in seizures 
(Elliott et al., 2009).   





TSC disease etiology, manifestation, and treatment are well documented in the literature. 
However, there is a scarcity of available evidence for healthcare utilization and expenditure in 
this population.  This dissertation study used a modified Anderson’s model of healthcare 
utilization and its theoretical framework to determine the factors that contribute to healthcare 
utilization and costs associated with illness and treatment.     
Andersen’s model has been used extensively and is important in understanding the 
reasons for excess healthcare utilization and expenditures when comparing groups of patients.   
For the purpose of this study, the main constructs from Anderson’s model to be used include 
environment, population or patient characteristics, and health service use.  The use of healthcare 
services among individuals with TSC with or without epilepsy (i.e., ED visits, inpatient 
hospitalizations) and healthcare expenditures (i.e., expenditures for ED visits and inpatient 
hospitalizations) was examined.   A modified version of Anderson’s model for this dissertation 
study is shown in Figure 2.  The framework to be examined includes predisposing factors, 
enabling factors, individual-specific healthcare needs, healthcare utilization, and costs 
(Anderson, 1995; Graves, 2009).   
Predisposing factors are socio-cultural characteristics (social structure, health beliefs, and 
demographic factors) that exist before an illness (Anderson, 1995).  When examining healthcare 
utilization, it is important that enabling resources such as health facilities and health personnel 
are available within the communities where people live and work (Anderson, 1995). Measures 
such as health insurance and income are important factors when analyzing enabling resources for 
healthcare utilization.  Aday and Anderson (1974) explained that the framework for examining 
access to care can be conceptualized as a process that includes an assessment of health policies 




(financing, education, and organization), characteristics of the healthcare system, the population 
at risk to the utilization of the health services being rendered, and consumer satisfaction. 
Among the predisposing factors, age and gender were examined in this dissertation 
research.  Insurance coverage (insured and uninsured), the health status of the patient, income, 
and accessibility to care were also examined as enabling factors.  Measures of need included 
individual medical needs and perceived severity of the medical needs (co-existing 
comorbidities).   Healthcare utilization and costs of services, such as inpatient hospitalizations 
and emergency department visits, are factors used to explain differences in outcomes (healthcare 
utilization and expenditures) for individuals with TSC with and without epilepsy. 
 
Figure 2 
Modified Anderson Behavioral Model 
 
Adapted from, Anderson, R. M. (1995). Revisiting the behavioral model of access to medical 
care: Does it matter? Journal of Health Care and Social Behavior, 36, 1-10. 




Summary of the Chapter 
The results of this literature review were congruent.  Healthcare utilization and 
expenditure in individuals with TSC and epilepsy are complex and not well-studied.  Treatment 
of TSC associated with epilepsy is considered difficult despite the availability of several options 
in the management of the disease.  Anderson’s model of healthcare utilization and its theoretical 
framework were used to determine the factors that contribute to healthcare utilization and costs 
associated with illness and treatment.     
  




Chapter 3: Methodology 
Introduction to the Chapter 
Estimating the economic burden associated with TSC can be challenging, due to the 
complexity of the disease, including the diversity of the patient population and the heterogeneity 
in the clinical disease manifestation, coupled with the existence of various comorbidities. This 
chapter presents the methodology, research design, institutional review board (IRB) application 
and approval process, and reliability and validity of the study, including information regarding 
the data collection process, data preparation, and the strategy for data analysis.  
Research Design 
The research described in this dissertation was performed as a retrospective, cohort study, 
to assess the differences in healthcare utilization and expenditures among individuals diagnosed 
with TSC with and without comorbid epilepsy, in the United States. Five years of data, obtained 
from the Nationwide Emergency Department Sample (NEDS), was used for this study. Each ED 
visit included up to 15 diagnosis codes, based on the International Classification of Disease, 9th 
revision, Clinical Modification (ICD–9–CM). According to the ED records, all patients with a 
diagnosis of TSC (ICD 9-CM code 759.5) and epilepsy (ICD 9-CM code 345), in any position, 
between 2010-2014 were abstracted. 
Baseline characteristics, including each patient’s sociodemographic information and 
comorbidities, were extracted, and the outcomes (healthcare utilization and expenditures) were 
measured. All utilization rates and adjusted healthcare costs for the TSC population sample were 
compared against those for patients with epilepsy as a comorbidity. The direct costs were 
determined based on the total healthcare expenditures and derived from the sum of all direct 
payments made for all healthcare services.  




Institutional Review Board and Data Use Agreement 
An institutional review board (IRB) application was submitted to the Nova Southeastern 
University IRB, and approval was received. After the receipt of IRB approval, data collection 
and extraction were initiated. The Agency for Healthcare and Research Quality’s (AHRQ) 
Healthcare Cost and Utilization Project (HCUP) nationwide Data Use Agreement (DUA) was 
completed before receiving access to the NEDS data set.  
Resources and Data Collection 
This dissertation examined current trends in healthcare utilization (for both the 
emergency department and inpatient admissions) and expenditures among individuals diagnosed 
with TSC, both with and without epilepsy, using data from the NEDS database. The data files are 
publicly available for download and use. NEDS data are distributed as fixed-width, ASCII-
formatted data files. The NEDS database represents one of the largest all-payer ED databases, 
containing national estimates for hospital-based ED visits, and was created as part of the AHRQ 
Healthcare Cost and Utilization Project [Healthcare Cost and Utilization Project (HCUP), 2011]. 
NEDS contains information from approximately 28 million ED visits, at 980 hospitals, providing 
a 20%-stratified sample of U.S. hospital-owned EDs. NEDS contains geographic, hospital, and 
patient characteristic information, as well as data regarding the nature of hospital visits (e.g., 
common reasons for ED visits, acute and chronic conditions, and injuries), and discharge 
information. The data are compiled from hospital billing records, from both state emergency 
department databases (SEDDs) and state inpatient databases (SIDs). SIDs include information 
regarding individuals who are initially treated in the ED and are subsequently admitted to the 
same hospital. SEDDs contain information regarding those ED visits that do not result in hospital 
admissions (i.e., treat-and-release visits and transfers to another hospital). 




These data facilitated the estimation of resource utilization associated with a relatively 
rare condition. Using databases, such as NEDS, can help understand the extent and pattern of 
inpatient and ED use among TSC patients and provides additional information regarding the 
reasons for such visits, including the primary diagnosis received during the ED visit and the 
outcome of the ED visit (e.g., treated and released, transfer to home health, or inpatient 
hospitalization). An analysis of these data allowed associations among TSC, healthcare 
utilization, and healthcare costs, to be inferred, using a previously unused method. 
Identification of the Study Sample 
 The data used in this study were obtained from the NEDS database. TSC patients were 
identified using the ICD 9-CM code 759.5. Data from the years 2010-2014 were obtained and 
relevant dataset extracted. The NEDS core data files, which contain records for 100 percent of 
ED visits, were linked with the NEDs supplemental inpatient file. A unique NEDS record 
identifier (KEY_ED) can be used to link a patient’s NEDS core file with the corresponding 
supplemental inpatient file. The inclusion criterion for this study was patients with TSC; 
therefore, all patients with a TSC diagnosis (ICD 9-CM code 759.5) were included in this study. 
Patients were excluded if the following data fields were missing from the dataset; age, gender, 
and total cost/charges. Figure 3 presents a flow diagram showing how the sample was identified. 
A total of 3,689 individuals met the inclusion criterion. After applying the exclusion criteria, a 






















Reliability and Validity 
For quantitative research, Creswell (2014) explained that employing accuracy verification 
can result in meaningful interpretations of the data. For this dissertation research, the standards 
used to stratify the data and the data collection methods will assure the data quality. To ascertain 
the reliability of the data files, the NIS utilized a systematic sampling design to construct the 
database. This sampling design was a self-weighted sample design, similar to random sampling 
methods. The self-weighted sample design is considered to be efficient because it ensures that 
the sample is representative of the population, based on several critical factors, including hospital 
factors (hospital-unidentified, census division, ownership, urban-rural location, teaching status, 
number of beds) and patient factors (diagnosis-related group, admission month). In addition, a 
systematic sampling design reduces the margin of error for estimates. The NEDS data is based 
on a stratified probability sample of hospital-owned EDs. 
Data Analysis 
SPSS version 24 was used for all statistical analyses. A descriptive analysis of the TSC 
patient samples with and without epilepsy was performed. Continuous and categorical variables 
were summarized using means and percentages, respectively. Multivariate analysis was 
conducted to compare the proportions of TSC patients with epilepsy to the proportions of TSC 
patients without epilepsy, with regards to the use of inpatient hospital (IP) care, emergency room 
(ER) use, and total expenditures. The healthcare utilization of TSC patients, both with and 
without epilepsy, was assessed by calculating the differences in the mean annual frequency of 
healthcare services during the study period, for each type of service. The epilepsy-specific direct 
healthcare costs were estimated as the differences in healthcare expenditures for all service types 
between TSC patients with epilepsy and those without epilepsy. To measure the relationships 




among categorical variables, chi-square analyses were used (inpatient hospital admissions and 
emergency room use), whereas  t-tests were used to assess continuous outcome variables (length 
of stay and annual expenditures) for the sub-group analyses of mean differences between TSC 
patients with and without epilepsy. Based on the conceptual framework applied in this study, the 
dependent variables will focus on the use of healthcare services among TSC patients with and 
without epilepsy, including the number of ED visits, the number of inpatient hospitalizations, 
and healthcare expenditures for ED visits and inpatient hospitalizations.  
Variables of Interest 
Dependent variables  
TSC and epilepsy diagnoses were identified in NEDS, using the Clinical Classifications 
Software (CCS) diagnosis codes, which were reported for each ED visit. The CCS is based on 
the ICD-9-CM system, the accepted clinical mechanism for the identification of diagnoses and 
claim submissions, which are tied to insurance reimbursement. The CCS maps ICD-9 codes 
(which are extracted from the clinical ED encounter discharge abstract) with nearly 260 
clinically meaningful diagnosis categories (Table 4). The CCS diagnosis code was selected as the 
preferred variable for identifying TSC and epilepsy diagnoses for this analysis, based on clinical 
applications and analytical feasibility. Although NEDS provides ICD-9-CM codes for up to 15 
diagnoses per emergency department visit, we used only the first diagnosis listed for this 
analysis. Senathirajah et al. (2011) explained that the first-listed diagnosis for an emergency 
department record indicates the code for the diagnosis, condition, problem, or other reason for an 
encounter/visit shown in the medical record that is thought to be chiefly responsible for the 
services provided. Other dependent measures of utilization include trends for ED visits and 
hospital inpatient days.  




 NEDS provides information regarding the charges for ED and inpatient services, which 
was used to identify the economic burden associated with ED visits and inpatient stays. Total ED 
charges included both ED visits that resulted in “treated and released” patient outcomes and ED 
visits that resulted in hospitalization at the same hospital. The total charges were adjusted for 
inflation, relative to the value of the US dollar in 2014. To calculate the inflation adjustment 
factor, the annual consumer price index (CPI) was utilized to transform/convert the total charges 
into 2014 constant dollars. The CPI was obtained from the Bureau of Labor Statistics (Bureau of 
Labor Statistics, US Department of Labor, 2019). 
Table 4 
ICD-9-CM Code Categorization 
 
Category CCS Code 
Psychiatric 650-670 
Cancer  11-47 
Cardiovascular Disease 53, 96-118, 213 
Endocrine Disease 48-52, 55, 58 
Gastrointestinal Disease 135, 138-146, 148-155, 214 
Respiratory Disease 122- 134 
Infectious Disease 1-10, 76 
Rheumatology 54, 201-206, 210 
Pulmonary 56, 116 
Autoimmune Disease 57 
Hematologic Disease 59-64 
Nervous System Disease 77-85, 94-95, 216, 227 




Ophthalmologic Disease 86-93 
Vascular Disease 119-121 
Nephrological Disease 156-166, 215 
Gynecological /Obstetrics 167-196, 218-224 
Dermatological Disease 197-200 
Injury  226-236, 239-240 
ICD-9-CM, International Classification of Disease, 9th revision, Clinical Modification; CCS, 
Clinical Classification Software 
Independent variables  
Gender (male and female) and age (all ages reported) were selected as the predisposing 
independent variables, based on the Anderson-Aday model. Age was categorized into infant (< 1 
year), pre-school (1–5 years), grade-school (6–9 years), pre-adolescent (10–13 years), adolescent 
(14–17 years), and adult (> 18 years) groups. Enabling variables included the health insurance 
coverage reported as the primary payer for both the ED and inpatient stay (categorized as 
Medicare, Medicaid, private, self-pay, no charge, or other) and socioeconomic status (median 
household income for the patient’s zip code, assigned by HCUP). The disposition status from the 
ED was also examined, categorized as discharged (patients treated and released from the ED), 
admitted (patients admitted to the same institution), or other (transferred, left against medical 
advice, died in the ED). The numbers and type of comorbidities reflected the need variables from 
the model. 
Summary of Chapter 
This chapter described the data set that was used during this dissertation research and 
how the research population was identified. This chapter also described the research measures 




and operationalization of variables and provided a profile of the study population and the 
analytical methods used to test and answer the proposed research questions and aims.  




Chapter 4: Results 
Introduction to the Chapter 
 This chapter presents the results of the statistical analyses performed to assess differences 
in the health service utilization and expenditures between TSC patients with epilepsy and those 
without epilepsy, as well as other predisposing, enabling, and need characteristics. This chapter 
also presents the results of multivariate analysis, which was used to test the hypotheses and 
identify the factors associated with health service utilization and expenditures. 
Description of the Study Population 
 Tables 5 and 6 presents the characteristics of the study population, in terms of predisposing 
(age, gender, and TSC diagnoses), enabling (expected primary payer), need (number of 
comorbidities), and health behavior/service use (the type of ED event and disposition from ED) 
factors. As shown in Table 5, among the 3,572 patients analyzed, 65.5% of the study population 
were TSC patients with epilepsy, compared with 34.5% of patients without epilepsy. Among the 
study population, 1,755 (49.1%) were men and 1,818 (50.9%) were women. Most patients (60.4%) 
in the study population were adults (age > 18 years), whereas 7.3% were adolescents (age 14-17 
years), 5.7% were pre-adolescent (age 10-13 years), 7.4% were grade school children (age 6-9 
years), 14.6% were pre-school children (age 1-5 years), and 4.6% were infants (< 1 year). 
Approximately 81% of patients had between one and ten comorbidities, 17% had between ten and 
twenty comorbidities, and 2.1% had greater than twenty-one comorbidities. Over half of the 
patients, 1,829 (51.2%), were treated and released from the ED after their initial hospital encounter. 
In contrast, 1,609 (45%) of patients were admitted to the same hospital during their initial ED visit. 
The expected primary payer for most patients (67%) was public health insurance (26% Medicare 
and 40.7% Medicaid), whereas private insurance accounted for 26%. Patient location was 




categorized based on the urban-rural classification scheme for U.S. counties, developed by the 
National Center for Health Statistics (NCHS), which emphasizes the distinction and differentiation 
of counties associated with large metropolitan areas (counties near metro areas with populations  
1 million), separating these counties into two categories; large, “central” metro (akin to inner cities) 
and large, “fringe” metro (akin to suburbs). Other NCHS classifications include medium 
metropolitan, small metropolitan, micropolitan, and counties that are neither metropolitan nor 
micropolitan. Approximately 31% (1,091) of patients lived in large, central, inner-city 
metropolitan areas, 25% (897) lived in large suburban metropolitan areas, and 23% (808) lived in 
medium metropolitan areas. Table 5 also presents the characteristics associated with the median 
household income for patients, based on their zip codes. As shown in this table, the patient 
distributions according to median household income were similar, with 891(25.2%) patients 
categorized in the 0–25th percentile (poorest population), 912 (25.8%) patients in the 26–50th 
percentile, 913 (25.9%) patients in the 51–75th percentile, and 774 patients in the 76–100th 
percentile (the wealthiest population). 
Table 5 
Characteristics of the Study Population 
 
 N % 
All PREDISPOSING 3,572 100.0 
              TSC Patient with Epilepsy 2,338 65.5 
              TSC Patient without Epilepsy 1,234 34.5 
Age (years)   
Infant (< 1) 164 4.6 
Pre-School (1–5) 520 14.6 
Grade School (6–9) 265 7.4 
Pre-Adolescent (10–13) 204 5.7 
Adolescent (14-17) 262 7.3 
Adult (18+) 2,157 60.4 




Gender   
Male 1,754 49.1 
Female 1,818 50.9 
Number of Co-Morbid Diagnoses    
1-10 Diagnosis 2,891 80.9 
11-20 Diagnosis 606 17 
>21 Diagnosis 75 2.1 
Number of Procedures on ED Inpatient Record   
1-5 procedures 828 23.2 
6-10 procedures 72 2.0 
>11 procedures 10 0.3 
Type of ED Event   
ED visit in which the patient was treated and released 1,829 51.2 
ED visit in which the patient was admitted to the same 
hospital 
1,609 45.0 
ED visit in which the patient was transferred to another 
short-term hospital 
124 3.5 
ED visit in which the patient was not admitted to the same 
hospital, destination unknown 
10 0.3 
Disposition from ED   
Routine 1,756 49.1 
Transfer to short-term hospital 124 3.5 
Transfer to other: includes Skilled Nursing Facility, 
Intermediate Care Facility, Home Health Care (HHC) 
61 1.7 
Against medical advice (AMA) 12 0.3 
Admitted as an inpatient to this hospital 1,609 45.0 
Not admitted to this hospital, destination unknown 10 0.3 
Expected Primary Payer   
Medicare 930 26.0 
Medicaid 1,455 40.7 
Private insurance 922 25.8 
Self-pay 134 3.8 
No Charge /Other 126 3.6 
Patient Location: NCHS Urban-Rural Code   
"Central" counties of metro areas with 1 million population 1,091 30.6 
"Fringe" counties of metro areas with 1 million population 897 25.2 




Counties in metro areas with populations of 250,000–
999,999 
808 22.7 
Counties in metro areas with populations of 50,000-249,999 326 9.1 
Micropolitan counties 258 7.2 
Not metropolitan or micropolitan counties 176 4.9 
Median Household Income for the Patient’s Zip Code   
0-25th percentile 891 25.2 
26th to 50th percentile 912 25.8 
51st to 75th percentile 913 25.9 
76th to 100th percentile 774 21.9 
ED, Emergency department 
 The primary reasons and diagnoses (Table 6) reported for the initial hospital encounter 
varied; however, more than one in five (26.1%) patients were diagnosed with epilepsy. Other 
notable reasons or diagnoses associated with the initial ED visit included congenital anomalies 
(6.0%), septicemia (2.9%), headache (2.5%), and pneumonia (2.5%). 
Table 6 
 
Primary Diagnosis at Initial Visit 
 
 N % 
Epilepsy; convulsions 933 26.1 
Other congenital anomalies 216 6.0 
Septicemia 102 2.9 
Headache; including migraine 89 2.5 
Pneumonia 89 2.5 
Fluid and electrolyte disorders 78 2.2 
Urinary tract infections 72 2.0 
Other nervous system disorders 69 1.9 
Abdominal pain 69 1.9 
Other upper respiratory infections 61 1.7 
Complication of device; implant or 
graft 
60 1.7 
Fever of unknown origin 58 1.6 
Other gastrointestinal disorders 58 1.6 
Nausea and vomiting 53 1.5 




Other injuries due to external causes 53 1.5 
Nonspecific chest pain 48 1.3 
Open wounds of head; neck; and trunk 48 1.3 
Superficial injury; contusion 45 1.3 
Aspiration pneumonitis; food/vomitus 44 1.2 
Other lower respiratory disease 41 1.1 
Other connective tissue disease 39 1.1 
Complications of surgical procedures 
or medical care 
35 1.0 
Mood disorders 35 1.0 
Schizophrenia and other psychotic 
disorders 
32 .9 
Skin and subcutaneous tissue infections 32 .9 
   
Characteristics Associated with Epilepsy 
 The characteristics of the study population, according to the presence or absence of 
epilepsy diagnosis, are presented in Table 7. Among the study population, 65.4% (n = 2,338) had 
at least one claim associated with an epilepsy diagnosis, whereas 34.5% (n = 1,234) had no 
history of epilepsy diagnoses. Medicaid was the expected payor for the majority of TSC patients 
with epilepsy and among all patients. The proportion of individuals with epilepsy was slightly 
higher (35.2 %) among males than among females (30.2%). Similarly, epilepsy diagnoses 
occurred more frequently (37.2%) among adults than among all other age groups. TSC patients 
with epilepsy demonstrated a significantly higher number of comorbidities compared with those 
without epilepsy. Specifically, 52.6% of TSC patients with epilepsy had an average of one to ten 
comorbid condition, whereas 11.8% had eleven to twenty comorbid conditions, and 1% had 
more than twenty-one comorbid conditions, as compared with 28.3% of TSC patients without 
epilepsy with an average of one to five comorbid condition, 5.2% with ten to twenty comorbid 
condition, and 1.1% with greater than twenty-one comorbid conditions. Overall, the prevalence 




of diseases associated with the central nervous system was higher among the study population 
than other comorbidities. Specifically, 38.9% of patients with epilepsy had a comorbid disease of 
the central nervous system. Respiratory diseases also had a high prevalence among the study 
population, although to a lesser extent than neuronal conditions. The total number of surgical 
procedures was significantly higher (66.9%) among TSC patients with epilepsy than among TSC 
patients without epilepsy (33.3%). 
 Logistic regression was performed to ascertain the effects of age and gender on the 
likelihood that the participants will have epilepsy. As shown in Table 7, age and gender were 
associated with increased odds of epilepsy diagnosis. The model was able to explain 39.0% of 
the variance in epilepsy diagnosis and correctly classified 65.4% of cases. Both age (except for 
pre-school children aged 1-5 years) and gender were significant cofactors (P < .001).  Females 
had a 1.7-fold increase in the odds to experience epilepsy compared with males.  
Table 7 
Characteristics of the Study Population by Epilepsy Status 
 
 TSC without Epilepsy TSC with Epilepsy Logistic Regression on Epilepsy 
 N % N % Sig OR 95% CI 
ALL PREDISPOSING 1,234 34.5 2,338 65.4    
Age (years)        
        Infant (<1) 63 1.8 101 2.8    
        Pre-School (1-5) 140 3.9 380 10.6 .479 0.888 (0.639–1.234) 
        Grade School (6-9) 74 2.1 191 5.3 .000 1.675*** (1.352–2.074) 
        Pre-Adolescent (10-13) 56 1.6 148 4.1 .003 1.541** (1.159–2.047) 
         Adolescent (14-17) 74 2.1 188 5.3 .007 1.563** (1.132–2.157) 
         Adult (18+) 827 23.2 1,330 37.2 .002 1.553** (1.168–2.064) 
Gender        
       Male 495 13.9 1,259 35.2    
       Female 739 20.7 1079 30.2 .000 1.725*** (1.498–1.986) 
Primary Payer        




       Medicare 303 8.5 627 17.7    
       Medicaid 434 12.2 1,021 28.6    
       Private Insurance 374 10.5 548 15.4    
       Self-Pay 70 2.0 64 1.8    
       No Charge/Other 50 1.4 76 2.1    
Number of Comorbid 
Diagnoses  
       
       1-10 Diagnoses 1,012 28.3 1,879 52.6    
       11-20 Diagnoses 184 5.2 422 11.8    
       >21 Diagnoses 38 1.1 37 1.0    
Primary Diagnosis 
Classification 
       
      Cancer 44 1.7 27 1.0    
      Cardiovascular Disease 84 3.2 58 2.2    
      Central Nervous System   89 3.4 1,029 38.9    
      Disease        
      Dermatological Disease 23 0.9 25 0.9    
      Endocrine Disease 24 0.9 85 3.2    
      Gastrointestinal Disease 79 3.0 106 4.0    
      Infectious Disease 50 1.9 83 3.1    
      Nephrological Disease 72 2.7 88 3.3    
      Ophthalmologic Disease 34 1.3 33 1.2    
      Psychiatric 57 2.2 89 3.4    
      Respiratory Disease 176 6.6 194 7.3    
Number of Procedures on 
ED Inpatient Record 
       
      1-5 Procedures 263 28.9 565 62.1    
      >6 Procedures 40 4.4 42 4.8    
Median Household Income 
for Patient’s Zip Code 
       
      0-25th percentile 306 8.7 585 16.6    
      26th to 50th percentile 334 9.5 578 16.4    
      51st to 75th percentile 298 8.4 615 17.4    
      76th to 100th percentile 273 7.7 501 14.2    
Sig, significance; OR, odds ratio; 95% CI, 95% confidence interval. p < .05, **p < .01, and ***. 
p < .001. 




Health Service Utilization 
 Health service utilization consisted of the use of inpatient services, the length of stay 
among those with at least one inpatient admission, and the use of the emergency room. Among 
the study group (Table 8), 51.2% (n = 1,829) had an initial hospital encounter in the ED, from 
which they were treated and released, whereas 45.0% (n=1,609) were admitted as an inpatient to 
the same hospital. A chi-square test of independence was performed, to examine the associations 
between gender, age, and the outcome of ED visits according to epilepsy status. The association 
between age and ED visit outcome was significant [X(5) = 37.4, p < .001]. Similarly, the 
relationship between gender and ED visit outcome was also significant [X(1) = 22.3, p < .001]. 
Among the patients who were admitted as inpatients, the majority were adults (48.6%). The 
proportion of TSC patients with epilepsy who were admitted to the same hospital during their 
initial ED encounter was higher (32.7%) than the proportion of TSC patients without epilepsy 
(12.3%).   
Table 8  
ED visit Outcomes 
 
 TSC without Epilepsy TSC with Epilepsy  
 N % N % Sig 
ALL PREDISPOSING 1,234 34.5 2,338 65.5  
ED visit in which the patient is treated and 
released 
764 21.4 1,065 
29.8 
 
 Sex      *** 
           Male 312 17.1 554 30.3  
           Female 452 24.7 511 27.9  
 Age (years)     *** 
           Infant (<1) 36 2.0 30 1.6  
           Pre-School (1-5) 113 6.2 207 11.3  
           Grade School (6-9) 53 2.9 114 6.2  
           Pre-Adolescent (10-13) 43 2.4 87 4.8  




           Adolescent (14-17) 58 3.2 113 6.2  
           Adult (18+) 461 25.2 514 28.1  
ED visit in which the patient is admitted to this 
same hospital 
441 12.3 1,168 32.7  
 Sex      *** 
           Male 173 10.8 643 40  
           Female 268 16.7 525 32.6  
 Age      *** 
           Infant (<1) 25 1.6 63 3.9  
           Pre-School (1-5) 20 1.2 133 8.3  
           Grade School (6-9) 18 1.1 64 4.0  
           Pre-Adolescent (10-13) 11 0.7 59 3.7  
           Adolescent (14-17) 14 0.9 67 4.2  
           Adult (18+) 353 21.9 782 48.6  
Note: * = p < .05, **p < .01, and *** = p < .001. Sig, significance; ED, Emergency department 
 Table 9 compares inpatient admissions according to epilepsy status and the various 
characteristics of the study population. Hospitalization was common among all patients; 
however, a high proportion (72.6%) of hospitalized patients was observed among those with 
epilepsy than among those without epilepsy.  
 To test the hypothesis that TSC patients with epilepsy are more likely to experience an 
inpatient hospital admission than those without epilepsy, a logistic regression analysis was 
performed. Table 9 presents the results of the logistic regression model for inpatient admissions. 
The multivariate analysis substantiated the initial observations that patients with epilepsy were 
more likely to experience a hospital admission, which was significant for grade school children, 
adolescents, and adults (P ≤ .05). The odds of hospital admission were nearly twice as high 
among those with epilepsy compared with those without epilepsy.  





Inpatient Admissions by Epilepsy Status 
 TSC without 
Epilepsy 
TSC with Epilepsy Logistic Regression on Inpatient 
Admission 
 N % N % Sig OR 95% CI 
ALL 441 27.4 1,168 72.6    
PREDISPOSING        
Age (years)        
Infant (<1) 25 1.6 63 3.9    
Pre-School (1-5) 20 1.2 133 8.3  1.138 (0.704-1.838) 
Grade School (6-
9) 
18 1.1 64 4.0 .*** 3.002 (1.845-4.883) 
Pre-Adolescent 
(10-13) 
11 0.7 59 3.7  1.605 (.937-2.748) 
Adolescent (14-
17) 
14 0.9 67 4.2 ** 2.421 (1.257-4.665) 
Adult (18+) 353 21.9 782 48.6 ** 2.160 (1.198-3.895) 
Gender        
Male 173 10.8 643 40.0    
Female 268 16.7 525 32.6 *** 1.897 (1.518-2.372) 
Note: * = p < .05, **p < .01, and *** = p < .001. Sig, Significance; OR, Odds ratio; 95% CI, 
95% confidence interval 
Length of Inpatient Stay 
 Table 10 compares the inpatient length of stay, according to epilepsy status and the 
characteristics of the study population. Overall, TSC patients with epilepsy had a mean length of 
stay of 4.94 days, compared with a mean length of stay of 6.76 days among those without 
epilepsy. A significant difference between groups was determined by an independent-samples t-
test. The results showed that the 1.82 day difference in the mean length of stay was significant 
[95% CI-825, 2.81; t(1750) = 3.59, P < .001].  
 To test the hypothesis that TSC patients with epilepsy would experience a longer average 
length of stay than those without epilepsy, a regression analysis was performed (Table 10). The 




results of the regression analysis revealed that the length of stay for patients with epilepsy was 
shorter than that for those without epilepsy. Both gender and age (6-8years old, 14-17 years old. 
and 18 years and older) were significantly associated with length of stay (P ≤ .05).  
Table 10 
Length of Stay Among Hospitalized Patients 
  
TSC without Epilepsy TSC with Epilepsy Logistic Regression on LOS 
 
Mean N Mean N Sig OR SE 
All 6.76 501 4.94 1251  
  
Epilepsy*** 








    
 
  
     Infant (<1) 6.81 26 3.74 66  
  
     Pre-School (1-5) 3.26 34 3.41 151  1.180 (0.737-1.889) 
     Grade School (6-9) 10.76 21 4.93 73 *** 2.017 (1.362-2.987) 
     Pre-Adolescent (10-13) 2.21 14 4.1 68 * 1.684 (1.016-2.792) 
     Adolescent (14-17) 6.88 17 4.28 75 ** 2.221 (1.233-4.000) 
     Adult (18+) 7 389 5.44 818 ** 2.062 (1.200-3.544) 
Gender  
    
 
  
     Male 9.43 191 5.21 688  
  
     Female 5.11 310 4.6 563 *** 2.067 (1.668-2.561) 
Note: * p < .05, **p < .01, and *** p < .001. Sig, significance; OR, Odds ratio; SE, standard 
error 
Total Expenditures by Status 
 The total expenditures per person were transformed to a logarithmic scale and 
standardized in constant dollars, using 2014 as the base year, to control for inflation associated 
with medical care costs (Bureau of Labor Statistics, 2019). The results are presented in 2014 
constant US dollars. 
 Tables 11 and 12 compare the mean annual expenditures for ED and inpatient stays (in 
2014 constant dollars), according to epilepsy status and predisposing, enabling, and need 
characteristics. Annual expenditures include the amounts paid by Medicaid, Medicare, private 




insurance, self-pay, and others. The overall mean annual expenditure for ED visits (Table 11) by 
TSC patients without epilepsy was $2,345.51, compared to $2,433.17 for TSC patients with 
epilepsy. An independent-samples  t-test was performed to examine the mean difference in 
annual expenditures for ED visits between TSC patients with and without epilepsy, which 
showed that the mean ED expenditure difference of $87.67 was not significant [95% CI -198.94, 
374.28; t(3285) = 0.60; P =.549]. TSC patients under the age of 18 who had epilepsy 
experienced larger ED expenditures than those without epilepsy. The population with the largest 
annual expenditures were patients with epilepsy whose primary classification diagnosis was 
cardiovascular disease. These individuals spent approximately $6,000 annually, which was more 
than twice the overall mean expenditure of $2,345-$2,433. High expenditures were also observed 
for patients without epilepsy who also had a diagnosis of cardiovascular disease ($3,851), 
although these patients spent less than their epileptic counterparts. Other diagnoses associated 
with high expenditures included rheumatological conditions and conditions of the central 
nervous system. For those individuals without epilepsy, gastrointestinal diseases were also 
associated with high costs. Medicare and self-pay patients incurred higher costs than patients 
using other methods of payment.  
Table 11 
Annual Emergency Department Expenditures According to Epilepsy Status 
  
TSC without Epilepsy TSC with Epilepsy 
 
Mean ($) N % Mean ($) N % 
All 2,345.51 1,153 35.1 2,433.17 2,134 64.9 
PREDISPOSING       
Age (years)       
     Infant (<1) 1,123.80 57 1.7 2,371.57 97 3.0 
     Pre-School (1-5) 1,414.85 128 3.9 1,736.20 351 10.7 
     Grade School (6-9) 1,551.40 69 2.1 1,910.71 174 5.3 
     Pre-Adolescent (10-13) 1,888.29 53 1.6 2,406.65 129 3.9 
     Adolescent (14-17) 2,157.21 65 2.0 2,499.77 174 5.3 




     Adult (18+) 2,704.06 781 23.8 2,708.90 1209 36.8 
Gender       
     Male 2,106.10 450 13.7 2,454.46 1155 35.1 
     Female 2,498.76 703 21.4 2,408.06 979 29.8 
Expected Primary Payer       
     Medicare 2,763.28 287 8.7 2,770.90 584 17.8 
     Medicaid 1,820.03 402 12.2 2,130.12 922 28.1 
     Private Insurance 2,555.06 347 10.6 2,575.22 495 15.1 
     Self-Pay 2,759.91 67 2.0 2,796.79 60 1.8 
     Other 2,163.12 41 1.2 2,350.99 68 2.1 
Primary Diagnosis 
Classification 
      
     Cancer 2,456.84 39 1.6 1,721.15 25 1.0 
     Cardiovascular Disease 3,851.35 79 3.3 6,033.04 50 2.1 
     Central Nervous System   
     Disease 
2,665.84 84 3.5 2,518.33 927 38.3 
     Dermatological Disease 1,477.91 20 0.8 2,661.63 19 0.8 
     Endocrine Disease 2,341.88 22 0.9 2,197.08 79 3.3 
     Gastrointestinal Disease 2,891.52 74 3.1 2,224.36 96 4.0 
     Infectious Disease 1,724.51 48 2.0 1,872.42 78 3.2 
     Nephrological Disease 2,538.80 69 2.9 2,299.46 79 3.3 
     Ophthalmologic Disease 2,137.88 33 1.4 1,011.22 31 1.3 
     Psychiatric 2,090.61 53 2.2 1,882.75 82 3.4 
     Respiratory Disease 1,812.22 160 6.6 1,891.37 179 7.4 
     Rheumatology 2,933.82 22 0.9 2,759.38 11 0.5 
Note: * = p < .05, **p < .01, and *** = p < .001. 
 For inpatient stays (Table 12), TSC patients without epilepsy had higher total 
expenditures ($63,520) compared with TSC patients with epilepsy ($40,248). An independent-
samples t-test was performed to determine whether a significant mean difference in annual 
expenditures existed for inpatient stays between TSC patients with and without epilepsy. The 
results showed a mean inpatient expenditure difference of $23,272.37, which was significant 
[95% CI -12567.24, 33977.50; t(1740) = 4.26, P< .001]. Among the study population, males 
without epilepsy experienced the highest total expenditures. Similarly, grade school children (6-9 
years) without epilepsy had a larger inpatient expenditure ($133,524) than all other age groups. 
High expenditures were also observed among infants without epilepsy ($99,202). TSC patients 
without epilepsy who had primary diagnoses of cancer ($151,710) and infectious disease 




($166,726) had the greatest total expenditures. These individuals’ costs were more than double 
the mean expenditure of $40,248–$63,520. High expenditures were also observed among 
patients with epilepsy with diagnoses of cancer ($94,542) and infectious disease ($75,305), 
although to a lesser extent than their non-epileptic counterparts. Medicare and Medicaid patients 
without epilepsy incurred higher costs than all other patients in the study population.   
 
Table 12 
Annual Inpatient Expenditures According to Epilepsy Status 
  
TSC without Epilepsy TSC with Epilepsy  
 
Mean ($) N % Mean ($) N % Sig 
All 63,520.45 497 28.5 40,248.08 1245 71.5 *** 
PREDISPOSING        
Age (years)        
     Infant (<1) 99,202.13 25 3.01.4 37,224.87 65 3.7  
     Pre-School (1-5) 41,177.48 34 2.0 31,744.97 151 8.7  
     Grade School (6-9) 133,524.08 20 1.1 38,283.38 73 4.2  
     Pre-Adolescent (10-13) 17,525.91 14 0.8 41,826.48 68 3.9  
     Adolescent (14-17) 59,155.03 17 1.0 42,510.97 75 4.3  
     Adult (18+) 61,416.27 387 22.2 41,904.73 813 46.7  
Gender        
     Male 95,261.03 190 10.9 39,607.38 685 39.3  
     Female 43,876.45 307 17.6 41,031.79 560 32.1  
Expected Primary Payer        
     Medicare 77,279.81 157 9.0 39,859.69 421 24.2  
     Medicaid 70,342.45 128 7.4 41,376.04 486 27.9  
     Private Insurance 51,559.69 170 9.8 36,120.85 266 15.3  
     Self-Pay 41,180.82 22 1.3 57,757.45 28 1.6  
     Other 42,697.84 16 0.9 45,953.32 43 2.5  
Primary Diagnosis 
Classification 
       
     Psychiatric 32,900.91 20 1.4 28,892.22 50 3.5  
     Cancer 151,710.42 38 2.7 94,542.66 25 1.8  
     Cardiovascular Disease 46,541.98 51 3.6 43,468.60 37 2.6  
     Endocrine Disease 19,370.55 20 1.4 21,808.86 59 4.1  
     Gastrointestinal Disease 47,911.71 37 2.6 46,437.73 73 5.1  
     Respiratory Disease 45,692.21 86 6.0 46,248.71 130 9.1  
     Infectious Disease 166,726.95 37 2.6 75,305.78 71 5.0  
     Central Nervous System   
     Disease 
34,143.43 18 1.3 32,992.34 495 34.7  




     Nephrological Disease 32,626.64 33 2.3 29,286.93 58 4.1  
Note: * = p < .05, **p < .01, and *** = p < .001. Sig, significance 
Summary of Chapter 
 This chapter presented the results of the analyses examining the characteristics associated 
with TSC patients with and without epilepsy, health service use, and expenditures. Bivariate 
analyses showed a higher proportion of patients with epilepsy used inpatient and emergency 
room services compared with those without epilepsy. However, the length of stay was longer 
among those who did not have epilepsy. The non-epilepsy group had higher mean expenditures 
associated with inpatient stays than those with epilepsy. A larger proportion of epileptic TSC 
patients experienced CNS comorbidities than non-epileptic patients.  




Chapter 5: Discussion & Conclusion 
Introduction to the Chapter 
 This chapter presents a summary of the dissertation study findings, a discussion of the 
findings, the relationship between this study and those reported in the existing literature, and the 
important conclusions that can be drawn from this study. This chapter also presents the 
implications for policy and practice, recommendations for further research, and the limitations, 
and delimitations of this study. The present study examined the healthcare utilization and 
expenditures associated with individuals diagnosed with TSC, comparing those with and without 
epilepsy. Using a modified Behavioral Model for healthcare utilization as a conceptual 
framework, the present study analyzed the healthcare utilization and expenditures data for TSC 
patients with and without epilepsy, obtained from the Nationwide Emergency Department 
Sample (NEDS). The study aimed to examine, analyze, quantify, and compare the healthcare 
utilization and expenditures of individuals diagnosed with TSC, with and without epilepsy, in the 
United States, using data obtained from the NEDS database. 
Discussion 
 This dissertation study addressed the following questions regarding healthcare utilization 
and expenditures among individuals diagnosed with TSC, with and without epilepsy: 
Question: What trends associated with healthcare utilization (emergency department use 
and inpatient admissions) and expenditures can be identified among individuals 
diagnosed with TSC, with and without epilepsy 
Aim 1: To determine the healthcare utilization (inpatient and emergency 
department) among individuals diagnosed with TSC, with and without epilepsy. 




Aim 2: To determine the specific costs associated with the care of these 
individuals. 
Aim 3: To determine the prevalence and impacts of predisposing comorbidities on 
hospital admissions and expenditures among individuals with TSC who are 
diagnosed with epilepsy.  
Aim 4: To determine the sociodemographic and patient dispositions among 
 individuals with TSC that are associated with epilepsy 
 This study contributes to the literature by providing information regarding the utilization 
of ED and inpatient services among TSC patients, in addition to data regarding the associated 
costs of treatment. A study conducted in 2013 showed that among TSC patients, the experience 
of seizures was very strongly associated with hospitalization (Lennert et al., 2013); therefore, the 
inpatient admissions and associated expenditures were expected to be high among TSC patients 
with epilepsy.  
Healthcare Utilization 
 Among the study population, the most common reasons for the initial ED visit were 
associated with epilepsy and other congenital anomalies. TSC patients with epilepsy were 
diagnosed with more comorbidities than those without epilepsy. Most ED visits were categorized 
as treat and release. Among those admitted as inpatients to the same hospital, the proportion of 
TSC patients with epilepsy was higher (72.6%) than the proportion of TSC patients without 
epilepsy (27.4%). The odds of hospital admission were nearly two-fold higher among those with 
epilepsy (OR and CI). This finding indicated that increased ED use among TSC patients with 
epilepsy may also lead to increased hospitalization. Contrary to expectations, however, individuals 




with epilepsy had a shorter average length of stay (4.94 days) than those without epilepsy (6.76 
days). This result is consistent with the findings from an earlier study by Lennert et al. (2013), 
which reported similar lengths of stay for neurologic-related hospitalization (6.03 days), compared 
with the length of stay among the control cohort for TSC-related hospitalization (6.80 days). This 
outcome could be attributed to the necessity of performing surgical procedures, comprehensive 
diagnostic testing, and other interventions, which often require more specialized care and the 
increased utilization of healthcare resources, leading to an increased length of stay. In addition, the 
length of stay among this population may also be attributed to unmeasured differences in the 
severity of comorbid conditions. Further research evaluating the clinical profiles and the drivers 
associated with prolonged inpatient stays among these patients improve our understand and expand 
the findings of this study. 
ED and Inpatient Expenditures 
 This study also compared the mean total ED and inpatient charges between TSC patients 
with and without epilepsy. The overall mean annual expenditure for ED visits by TSC patients 
without epilepsy was slightly lower than that for patients with epilepsy. However, for an 
inpatient stay, TSC patients without epilepsy had higher total expenditures than TSC patients 
with epilepsy. Although individuals without epilepsy had higher average inpatient expenditures 
than those with epilepsy, the absence of epilepsy as a comorbidity did not increase the odds of 
being included in the highest expenditure group. The odds of high expenditures were increased 
among patients with pre-existing conditions, such as cancer and infectious diseases. Grade 
school (aged 6-9 years) TSC patients without epilepsy had higher annual expenditures than all 
other age groups. Nearly half (46.3%) of TSC patients with epilepsy were covered by public 




health insurance (Medicare and Medicaid), compared with less than one-quarter (20.7%) of TSC 
patients without epilepsy. Among all patients, a higher proportion (67%) had Medicaid as the 
primary payer, suggesting that these patients were likely receiving disability compensation or 
were considered to have low incomes. This finding also suggested that public payers account for 
larger proportions of ED visits that lead to inpatient admissions among this population. This 
outcome is consistent with a study conducted by Wen et al. (2017), which reported that ED visits 
leading to inpatient admissions for more than 90% of pediatric epilepsy patients were covered by 
Medicaid. To our knowledge, no studies among the TSC-specific health services research 
literature has examined the demographic characteristics and costs among individuals on public 
insurance, especially Medicare and Medicaid, even though this may describe a high proportion 
of the TSC population.  
Implications for Health Policy and Practice 
 Because TSC is frequently accompanied by comorbid health conditions, such as epilepsy 
and other chronic physical illnesses, a patient may be treated by numerous specialists. Although 
access to and the use of multiple healthcare providers is often perceived as good access to care, 
this situation can also be associated with many challenges, including additional burdens on 
caregivers and families. Policymakers should adopt and implement. Advocacy groups, such as 
the TSC Alliance, have developed information to help individuals with TSC identify specialty 
clinics and clinicians (TSC Centers of Excellence) and to actively engage with their physicians 
and other health providers (tsalliance.org, n.d.). These resources provide tools to help TSC 
patients and their families become active participants in their healthcare, by asking questions 
about the relationships between conditions, medication interactions and side effects, and 
facilitating communications between primary care physicians and specialists (tsalliance.org, 




n.d.). Despite the availability of these resources, additional resources and programs remain 
necessary to improve patients’ access to these specialized clinics. A study conducted by Rentz et 
al. (2015), reported that, although over 40 TSC Centers of Excellence have been designated in 
the United States, almost three-fourths of adult patients and half of pediatric patients in their 
study lived further than 100 miles away from a TSC clinic. The challenges of living with 
multiple health conditions also indicate the need for continuous health education for TSC 
patients and their caregivers, in addition to multidisciplinary medical team input (Northrup & 
Krueger, 2013). Patients often face significant difficulties in identifying the right medical 
expertise necessary to comprehensively and effectively manage their care. As TSC patients grow 
from childhood into adulthood, care coordination among various specialties can be critical 
during the transition from pediatric to adult healthcare services (Both et al., 2018). Care 
coordination can include the inclusion and evaluation of the viewpoints of the patients and their 
families, to gain insights into the difficulties associated with the care of these patients and the 
development of interventions that might improve the transition process to adult services. One 
possible solution for effective and efficient care coordination is the availability of facilities and 
clinics capable of treating both children and adult TSC patients, which would ensure efficient 
transitional healthcare and appropriate and continuous surveillance and disease management. 
State agencies can provide support for the development and delivery of health education 
programs and educational materials. For example, the Managing Epilepsy Well (MEW) network 
is a Centers for Disease Control and Prevention (CDC) research center program that aims to 
provide national leadership for the development, testing, and distribution of innovative self-
management programs and training for epilepsy professionals, families, and individuals affected 
by epilepsy. Project UPLIFT, a program within the MEW network, provides self-management 




programs that aim to empower people with epilepsy to manage and improve their mental health 
and quality of life. Similar programs can be expanded to include specialized and focus education 
and training for individuals with epilepsy coupled with rare genetic diseases, such as TSC. The 
results from this study can be used by policymakers and organizations to focus further 
investigations into the costs associated with care management and care delivery patterns among 
individuals with TSC. 
Implications for Future Research 
 This analysis of health service utilization and expenditures among TSC patients with or 
without epilepsy highlights areas of potential future research. First, additional studies, using 
similar methods and other claims datasets, remain necessary to assess the generalizability of the 
study findings. The present study documented the increased odds of inpatient hospitalizations 
and emergency room use among TSC patients with epilepsy compared with those without 
epilepsy. Future studies should examine patterns of repeated hospital events, which could 
facilitate the identification of opportunities for the prevention of these events. Additional 
analyses of race/ethnicity differences, outpatient services, medication use, and ambulatory care 
among TSC patients, along with precise measurements of the various comorbidities, remain 
necessary to better understand the healthcare utilization and expenditures among this population.  
Research identifying barriers to medical and social service access can indicate specific targets for 
policy solutions and ensure equitable access to healthcare. 
 The findings from this dissertation study have raised additional questions regarding the 
factors that affect the lengths of hospital stays and annual expenditures. Future studies should 
include all diagnoses, treatments, and interventions in the claims data and should explore other 
comorbidity measures, especially given the unexpected result that TSC patients without epilepsy 




experienced significantly longer lengths of stay and increased mean inpatient expenditures than 
patients with epilepsy, which may reflect unmeasured differences in the overall health status. 
 
Limitations and Delimitations 
To conduct this dissertation research, data were obtained from the largest, publicly 
available, all-payer database, for the period 2010-2014. All individuals diagnosed with TSC, 
either with or without epilepsy as a comorbidity, were included. Variations in demographic data 
were expected but were not controlled for during this analysis. Limitations include selection bias, 
which can occur because the outcomes being observed have already occurred at the time of 
selection. In addition, the use of retrospective, secondary data presents limitations, due to the 
lack of control in the selection of study variables and sampling and collection methods. Despite 
many advantages, the NEDS data is limited because it uses discharge-level, rather than a person-
level, data. Therefore, multiple visits by individuals within the study population could not be 
distinguished. 
This dissertation study is delimited to individuals with TSC associated with epilepsy. The 
decision to examine a specific data set and variables of interest also delimit the dissertation 
study. The NEDS data contains encounter-level records, not patient-level records; therefore, 
individual patients who visit the ED multiple times in one year may be present in the NEDS 
database multiple times. No uniform patient identifiers are available that would allow a patient-
level analysis for the identification of individuals associated with more than one ED visit. The 
NEDs dataset did not include prescription medication use or associated expenditures or 
information regarding patient encounters with outpatient services and specialist clinics. 
Therefore, these results may not reflect the experiences of those who used outpatient services 
and specialist clinics, resulting in an incomplete assessment of healthcare utilization and 




expenditures. Missing values from the obtained data can compromise the quality of estimates, 
resulting in bias and the inaccurate representation of inpatient and ED utilization patterns. 
Finally, racial/ethnic differences could not be accounted for in this study, due to the lack of 
information on race in the available data. 
Conclusion 
 TSC inflicts a burden on society, imposing a significant burden on both individuals who 
have the condition and their families and caregivers. Despite the availability of FDA-approved 
medications for the treatment of TSC and its associated comorbidities, the results from this 
dissertation study suggested significant healthcare utilization and expenditures among this 
patient population. A better understanding of the utilization and cost patterns associated with 
TSC would facilitate the efficient allocation of resources while improving overall care for these 
patients.  
TSC patients visit EDs for various reasons, beyond those associated with their primary 
condition or disease. ED visits among TSC patients with epilepsy were associated with increased 
hospitalization rates than those among TSC patients without epilepsy; however, for an inpatient 
stay, TSC patients without epilepsy experienced higher total expenditures than TSC patients with 
epilepsy. The increased expenditure among TSC patients without epilepsy may be attributable to 
the treatment of many underlying comorbidities. Access to medical and social services and the 
burden of healthcare utilization and expenditures among TSC patients have been understudied, 
and future research should examine the impacts of these critical factors (socioeconomic factors, 
care management, delivery, and cost patterns among individuals on public insurance, especially 
Medicare and Medicaid, versus private insurance) to develop solutions and strategies that can 
ensure the equitable access to healthcare. 
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